Anthracycline‐Induced Cardiomyopathy in Adults
Authors:
- 1 July 2015
- journal article
- Published by Wiley in Comprehensive Physiology
- Vol. 5 (3) , 1517-1540
Abstract
Anthracyclines are one of the most commonly used antineoplastic agent classes, and a core part of the treatment in breast cancers, hematological malignancies, and sarcomas. Their benefit is decreased by their well‐recognized cardiotoxicity. The purpose of this review is to outline the presentation, mechanisms, diagnosis, and treatment of anthracyclines‐induced cardiotoxicity. Symptomatic heart failure occurs in 2% to 5% of patients treated with anthrayclines and may be higher in older patients or patients with cardiovascular risk factors. The mechanisms involved in anthracycline‐induced cardiotoxicity involve myocyte loss by apoptosis in the presence of a limited regenerative capacity. Once symptomatic, anthracycline‐induced cardiotoxicity is associated with markedly decreased survival. Left ventricular ejection fraction (LVEF), mostly determined using echocardiography, is used to monitor patients treated with anthracyclines. As more than 1/3 of patients treated with anthracyclines do not recover their baseline LVEF once it is decreased, more sensitive echocardiographic indices of LV function such as myocardial deformation or biomarkers have been studied in patients monitoring. Cardioprotective treatments such as angiotensin‐converting enzyme inhibitors, beta‐blockers, iron chelators, statins, and metformin are also the topic of research efforts. © 2015 American Physiological Society. Compr Physiol 5:1517‐1540, 2015.Keywords
This publication has 206 references indexed in Scilit:
- Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemiaCancer, 2013
- Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood CancerJAMA, 2013
- Peak oxygen consumption and long‐term all‐cause mortality in nonsmall cell lung cancerCancer, 2010
- Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisoloneCancer, 2005
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Cardiac Toxicity 4 to 20 Years After Completing Anthracycline TherapyJAMA, 1991
- Acute arrhythmogenicity of doxorubicin administrationCancer, 1987
- Effects of first-dose doxorubicin on cardiac rhythm as evaluated by continuous 24-hour monitoringCancer, 1985
- Doxorubicin CardiotoxicityJAMA, 1978
- A clinicopathologic analysis of adriamycin cardiotoxicityCancer, 1973